Research involving incretin-based therapies has shown reductions in: waist circumference, visceral fat, liver fat, and total body fat percentage
Anecdotal reports from notable figures like Andrew Huberman, who discussed using BPC-157 for L5 vertebral compression pain and reported pain elimination after just two injections, suggest potential nerve-related benefits
The primary completion of TRIUMPH-1 is expected around May 2026, with NDA submission projected for Q4 2026 to Q1 2027
Formulation alternatives may provide relief: Different tablet formulations with alternative inactive ingredients may be better tolerated Liquid preparations can be easier to tolerate and allow flexible dosing Intramuscular injections completely avoid the gastrointestinal tract and are particularly useful for those with absorption issues (such as pernicious anaemia or malabsorption) or persistent oral intolerance Review inactive ingredients: Examine the supplement label for potential irritants or allergens
Reducing the amount of prostaglandins reduces pain, fever or swelling
Current evidence is more supportive of using biweekly doses as a maintenance strategy only
